shenzhen salubris pharmaceuticals co., ltd.-九游会

 shenzhen salubris pharmaceuticals co., ltd.-九游会

major breakthroughs in the field of chronic heart failure

jk07 is an nrg-1 (neuregulin-1) fusion antibody drugwhich is independently developed by salubris biotherapeutics inc. and hasindependent intellectual property rights in major countries/regions around theworld. the indication to be developed is chronic heart failure.

latest news

knowledge about chronic heart failure

cardiovascular disease is still the first cause of death in the world. currently, there are about 26 million patients with heart failure in the world, including about 13.7 million patients in china and about 6.5 million patients in the united states

learn more

project progress

sal951 project introduction

learn more
网站地图